By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

He Xiaopeng: XPENG-W to Skip L3-lv. Autonomous Driving, Directly Deploy L4 Mass Production; Annual R&D Investment Expected to ...

Hangzhou Sciwind Biosciences Co., Ltd. ('Sciwind Biosciences') today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new-generation ...

Those were in great demand at the beginning of the pandemic, and generated gobs of money for Pfizer. Demand has waned, though ...

SHANGHAI, Feb 24 () - Pfizer has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ‌ecnoglutide, ...

Agreement worth up to $495 million is part of a growing number of Chinese deals with global pharma giants as the country ...

Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity medicine.

SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said on WeChat on Friday, boosting ...

China has approved Pfizer's GLP-1 treatment ​Xianweiying for long-term weight management in overweight or ‌obese adults, the ...